Phenotypic whole-cell screening identifies a protective carbohydrate epitope on Klebsiella pneumoniae.
Berry, Sophia K
Bartholdson Scott, Josefin
Tabor, David E
Grant, Andrew J
Informa UK Limited
MetadataShow full item record
Berry, S. K., Rust, S., Caceres, C., Irving, L., Bartholdson Scott, J., Tabor, D. E., Dougan, G., et al. (2022). Phenotypic whole-cell screening identifies a protective carbohydrate epitope on Klebsiella pneumoniae.. MAbs https://doi.org/10.1080/19420862.2021.2006123
The increasing global occurrence of recalcitrant multi-drug resistant Klebsiella pneumoniae infections warrants the investigation of alternative therapy options, such as the use of monoclonal antibodies (mAbs). We used a target-agnostic phage display approach to K. pneumoniae bacteria lacking bulky, highly variable surface polysaccharides in order to isolate antibodies targeting conserved epitopes among clinically relevant strains. One antibody population contained a high proportion of unique carbohydrate binders, and biolayer interferometry revealed these antibodies bound to lipopolysaccharide (LPS). Antibodies that bound to O1 and O1/O2 LPS were identified. Antibodies were found to promote opsonophagocytic killing by human monocyte-derived macrophages and clearance of macrophage-associated bacteria when assessed using high-content imaging. One antibody, B39, was found to protect mice in a lethal model of K. pneumoniae pneumonia against both O1 and O2 strains when dosed therapeutically. High-content imaging, western blotting and fluorescence-activated cell sorting were used to determine binding to a collection of clinical K. pneumoniae O1 and O2 strains. The data suggests B39 binds to D-galactan-I and D-galactan-II of the LPS of O1 and O2 strains. Thus, we have discovered an mAb with novel binding and functional activity properties that is a promising candidate for development as a novel biotherapeutic for the treatment and prevention of K. pneumoniae infections.
Klebsiella pneumoniae, Phage display, antimicrobial resistance, lipopolysaccharide, monoclonal antibody, Animals, Antibodies, Bacterial, Drug Resistance, Multiple, Bacterial, Epitopes, Humans, Klebsiella Infections, Klebsiella pneumoniae, Lipopolysaccharides, Macrophages, Mice, Opsonization
Is supplemented by: https://doi.org/10.17863/CAM.78423
This work was funded by AstraZeneca (MedImmune PhD) and the Cambridge Biomedical Research Centre.
External DOI: https://doi.org/10.1080/19420862.2021.2006123
This record's URL: https://www.repository.cam.ac.uk/handle/1810/330649
All rights reserved
Licence URL: http://www.rioxx.net/licenses/all-rights-reserved
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: firstname.lastname@example.org